Teva Pharmaceutical Industries (NYSE:TEVA) Research Coverage Started at TD Cowen

TD Cowen started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report report published on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $55.00 price target on the stock.

A number of other equities research analysts have also issued reports on TEVA. Barclays upped their price target on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Oppenheimer assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price objective on the stock. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, UBS Group lifted their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

Teva Pharmaceutical Industries Stock Up 0.4%

Teva Pharmaceutical Industries stock opened at $39.48 on Thursday. The business’s 50-day moving average price is $37.04 and its 200 day moving average price is $34.12. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The firm has a market cap of $46.01 billion, a price-to-earnings ratio of 65.80, a price-to-earnings-growth ratio of 3.77 and a beta of 0.89. Teva Pharmaceutical Industries has a 52 week low of $18.83 and a 52 week high of $40.79.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 1.93 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 374,959 shares of company stock valued at $14,644,285 in the last quarter. 0.54% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $9,126,000. TD Asset Management Inc increased its stake in shares of Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after acquiring an additional 118,075 shares during the last quarter. WCM Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the period. Swiss National Bank raised its holdings in shares of Teva Pharmaceutical Industries by 28.7% during the 1st quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock worth $127,344,000 after acquiring an additional 941,700 shares during the period. Finally, iA Global Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 43.8% during the 1st quarter. iA Global Asset Management Inc. now owns 299,035 shares of the company’s stock valued at $9,007,000 after acquiring an additional 91,026 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Ecopipam data strengthen Teva’s pipeline prospects. New analyses showed that approximately 70% of pediatric Tourette syndrome patients experienced clinically meaningful tic reduction within eight weeks. An interim 18-month extension study showed a mean 45.6% reduction in tic-severity scores, with no new safety signals. The results support ecopipam’s potential as a differentiated, non-antipsychotic treatment, although it remains investigational and is not yet approved. Teva Presents New Efficacy and Safety Data with Ecopipam
• Positive Sentiment: Analyst sentiment improved. TD Cowen initiated coverage with a Buy rating and a $55 price target, implying substantial upside from the recent trading level. Separately, the reported consensus target increased 24.24% to approximately ₪41.82, reinforcing a favorable view of Teva’s valuation and growth outlook.
• Positive Sentiment: Biosimilar collaboration expands future growth opportunities. Teva and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates globally, including candidates referencing Fasenra and Ilaris. The agreement could broaden Teva’s specialty-medicine pipeline and support longer-term revenue growth, though development and regulatory milestones remain ahead. Samsung Bioepis and Teva Expand Strategic Partnership
• Neutral Sentiment: A Journal of Child Neurology review highlighted ecopipam’s selective D1-receptor mechanism and potential advantages over antipsychotic therapies, but the review is supportive scientific context rather than new clinical or regulatory approval. Journal of Child Neurology Review

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.